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Objective: In this study, we investigated the relationship between left ventricular mass and
insulin resistance in obese patients.
Methods: A total of 90 subjects, 66 women, and 24 men, with an age range from 24 to 56 years,
were enrolled in the study. Forty-nine patients were in the obesity group whose body mass
index (BMI) was >29.9 kg/m2 and 41 subjects were in the control group with a BMI <25 kg/m2.
All of them were normotensive, nondiabetic, and did not have any cardiovascular disease.
They were not taking any medication. Weight, height, and waist circumference were
measured and BMI was calculated. Plasma glucose, insulin, serum total, high-density
lipoprotein (HDL) and low-density lipoprotein (LDL) cholesterol, and triglyceride levels were
measured, and insulin resistance was calculated via homeostasis model of assessment-
estimated insulin resistance (HOMA-IR). Subjects were examined by echocardiography and
left ventricular mass (LVM) and index (LVMI) were calculated with Devereux formula.
Results: Insulin levels, HOMA-IR, LVM, and LVMI were signiﬁcantly higher in obesity group
( p < 0.01). Fasting glucose, triglyceride, fasting insulin levels, and waist circumference did
not correlate with LVMI.
Conclusion: In conclusion, though ﬁndings of the present study suggest increased left
ventricular hypertrophy (LVH) in obese subjects compared to controls, it appears that the
increased LVM or LVH is not linked to BMI and insulin resistance in this study population.
# 2015 Cardiological Society of India. Published by Elsevier B.V. All rights reserved.
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Cardiovascular disease (CVD) constitutes one of the major
causes of deaths and disabilities, globally claiming 17.3 million
lives a year. Incidence of CVD is expected to rise to 25 million
by 2030.1 In 2008, 30% of all global deaths is attributed to
CVD. Death caused by cardiovascular diseases is also higher in§ This work was carried out at the Okmeydani Training and Researc
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0019-4832/# 2015 Cardiological Society of India. Published by Elsevierlow- and middle-income countries, as over 80% of all global
deaths caused by cardiovascular diseases occurred in those
countries.2–4 Changes in the left ventricular structure increase
the risk of cardiovascular diseases and death.5 The risk of
acute myocardial infarction, congestive heart failure, sudden
death, ventricular ectopy, serious arrhythmias, and other
cardiovascular events increases sixfold to eightfold with the
occurrence of left ventricular hypertrophy (LVH).6,7h Hospital, Istanbul, Turkey.
 B.V. All rights reserved.
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poses a serious risk for an increase in cardiovascular diseases
and deaths caused by them.8 LVH can be prevented by
eliminating the factors leading to increased LVM, but the nature
of the factors that cause an increase in LVM is yet to be
completely understood among normotensive and even among
hypertensive individuals.9,10 A prior study reports that no
change in the LVM was observed in 25–30% of individuals with
high blood pressure. These observations support the views that
there are other metabolic and genetic factors effective in cardiac
mass increase.11
Obese patients have persistent myocardial wall stress
because of an increase in circulatory volume and minute
volume.12 There are studies suggesting a relationship between
obesity and cardiac mass increase as well.13,14 Duration of
obesity is signiﬁcantly correlated with LVH.15 In vivo studies
have shown that insulin resistance (IR) and hyperinsulinemia
have effects on LVM.16,17 Additionally, in vitro studies have
shown that with the IR-associated hyperinsulinemia impact, an
increase is observed in sympathetic stimulation, peripheral
vascular resistance, renal sodium retention, cardiac workload,
and the anabolic effect on cardiac proteins.17,18 Some studies
have determined an independent relationship between insulin
level and cardiac mass.18,19However, it has not been completely
proven that IR is an independent indicator of the LVM
increase.20
According to the TEKHARF and the TURDEP I studies
conducted in Turkey, prevalence of obesity was 28% and 32%,
respectively.21,22 TURDEP II study reported that obesity in
Turkey increased by 40% compared to that reported in 1998,
and that overweight and obese patients constitute 2/3 of the
Turkish population.22 Therefore, the aim of our study was to
investigate the relationship between obesity, a signiﬁcant
health issue in Turkey, and IR, hyperinsulinemia, blood lipid
level disorders, and LVM, which are commonly associated with
obesity.
2. Materials and methods
The study was approved by the Institutional Ethics Commit-
tee. Written informed consent was obtained from each
subject following a detailed explanation of the protocol of
the study. All study procedures were conducted in accordance
with the ethical principles stated in the ‘‘Declaration of
Helsinki’’.
The study included 49 obese patients whose body mass
indices (BMI) were equal to or greater than 30 kg/m2 and
41 healthy subjects with BMI < 25 kg/m2. The participants
included in the study did not have history of hypertension,
diabetes (familial or self), or drug therapy. Patients with blood
pressure over 140/90 mmHg23 and fasting plasma glucose level
over 100 mg/dl were excluded from the study. The thyroid
function tests, urea, and creatinine levels of the patients were
within the normal range. There was no history of smoking in
either patient or control groups. Atrial ﬁbrillation, presence of
intraventricular electrodes, ischemic heart disease, hypertro-
phic cardiomyopathy, congenital heart disease, valve pros-
theses, chemotherapy, pericarditis, intracardiac masses or
thrombi, moderate or severe valvular stenosis or regurgitation,cor pulmonale, pulmonary thromboembolism, or heart failure
were excluded from study.
Age and gender information of all individuals were
recorded. Weight measurements were made with thin
clothing and no shoes on the same scale (Arzum Peso Model
AR535, China, 2008). Height measurements were made bare
foot. BMI was calculated with the weight (kg)/height2 (m)
formula. Waist circumference (WC) was measured with a
measuring tape at the level of the umbilicus. Blood pressure of
the patients was measured from both arms after a rest of at
least 15 min using a sphygmomanometer (Erka).
Glucose, total, very-low-density lipoprotein (VLDL) and high-
density lipoprotein (HDL)-cholesterol, triglyceride, and insulin
levels of the patients were measured in the venous blood
sample drawn after 12-h fasting by a clinical biochemistry
otoanalyzer (Olympus AU2700). Low-density lipoprotein (LDL)-
cholesterol value was calculated using the Fridewalt formula.24
Insulin levels were measured via chemiluminescence
method via Beckman Coulter DXİ 800 (Miami, USA 2006)
device in the serum sample obtained from venous blood after
10 min of centrifugation at 3000 rpm. In each subject, the
degree of IR was estimated at the baseline by homeostasis
model of assessment (HOMA) method described by Matthews
et al.25 In particular, a homeostasis model of assessment-
estimated insulin resistance (HOMA-IR) score was computed
with the formula of ‘‘fasting plasma glucose (mmol/L) 
fasting serum insulin (mU/L) divided by 22.5900.25
All of the patient and control group participants received
echocardiography (GE Vivid 3 pro, Indiana, USA). In case of 10
or more cycles, left ventricular diastolic diameters and
thickness of posterior wall and septum in diastole in 2D
parasternal long-axis position were measured by using
2.5 MHerz probes in the left lateral decubitus position.
LVM was calculated via Devereux formula.26 LVM index
(LVMI) was calculated as LVM divided by the body surface area.
Males with LVMI >134 g/m2 and females with LVMI >110 g/m2
were considered to have LVH.26
Statistical analyses were conducted using the NCSS
(Number Cruncher Statistical System) 2007 and PASS (Power
Analysis and Sample Size) 2008 statistical software packages
(UTAH, USA). Unpaired t test and Mann–Whitney U test was
used for comparisons based on the distribution pattern of the
numerical data. Chi-square test was used to compare
categorical data. Associations between the parameters were
evaluated with the Pearson and Spearman's correlation
analyses where appropriate. The results were evaluated as
signiﬁcant when p < 0.05 within a 95% conﬁdence interval.
3. Results
3.1. Baseline characteristics
The mean age of the obese group was 36.9  7.61 years (range
25–56 years) and of the control group was 34.17  7.77 years
(range 24–56 years), with no signiﬁcant difference between
groups ( p = 0.097). There were 40 (81.6%) females and 9 (18.4%)
males in the obese group; and 26 (63.4%) females and 15 (36.6%)
males in the control group. The groups did not differ
signiﬁcantly in terms of gender distribution ( p = 0.052).
Table 1 – Blood biochemistry findings in obesity and control groups.
Control group
(n = 41)
Obesity group
(n = 49)
p value
Mean  SD (median) Mean  SD (median)
Glucose (mg/dl) 82.07  9.33 87.84  8.69 0.003
Total cholesterol (mg/dl)a 178.39  30.73 197.39  36.98 0.01
LDL (mg/dl)a 98.95  24.79 115.73  33.75 0.01
VLDL (mg/dl)b 18.12  12.86 (13) 28.98  13.93 (26) 0.0001
HDL (mg/dl)a 64.59  17.07 50.98  8.54 0.0001
Triglyceride (mg/dl)b 81.76  46.91 (62) 144.49  69.02 (137) 0.0001
Insulin (mU/mL)b 5.82  2.75 (5.6) 12.95  8.05 (10.95) 0.0001
HOMA-IRb 21.26  11.55 (20.93) 50.75  32.13 (41.76) 0.0001
SD: standard deviation; LDL: low-density lipoprotein; VLDL: very-low-density lipoprotein; HDL: high-density lipoprotein; HOMA-IR:
homeostasis model of assessment-estimated insulin resistance.
a Student t test.
b Mann–Whitney U test.
Table 2 – The echocardiographic findings in obesity and
control groups.
Echocardiographic
ﬁndings
Control
group
(n = 41)
Obesity
group
(n = 49)
p value
Mean  SD Mean  SD
IVST 0.88  0.11 1.05  0.14 0.0001
LVID 4.39  0.54 4.92  0.49 0.0001
LPWT 0.86  0.14 1.02  0.17 0.0001
LVM 123.84  28.42 191.82  44.15 0.0001
LVMI 74.6  14.19 95.31  17.83 0.0001
IVST: interventricular septal thickness; LVID: left ventricular
internal diameter at diastole; LVPWT: left ventricular posterior
wall thicknesses; LVM: left ventricular mass; LVMI: left ventricular
mass index.
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females and 37.76  7.96 kg/m2 for males; and the waist
circumference of females was 112.35  10.87 cm and of males
was 117.22  18.08 cm. These values in the control group were
20.97  1.76 kg/m2, 21.85  1.90 kg/m2, 72.15  5.72 cm, and
81.86  9.96 cm, respectively. The control group and the
obesity group were signiﬁcantly different in terms of their
BMI and WC values ( p = 0.0001; p = 0.0001; p = 0.0001;
p = 0.0001, respectively).
The mean BMI of the overall study population was 30.2
 9.34 kg/m2 for all cases, 37.66  5.88 kg/m2 for obesity group
and 21.29  1.84 kg/m2 control group; and the waist circum-
ference of all cases was 96.14  21.71 cm, of obesity group was
113.24  12.42 cm, and of control group was 75.71  8.81 cm.
The control group and the obesity group were signiﬁcantly
different in terms of their BMI and WC values ( p = 0.0001;
p = 0.0001, respectively).
3.2. Blood biochemistry ﬁndings
Plasma glucose, total, LDL and VLDL cholesterol, and triglyc-
eride levels of the control and the obesity groups were
compared, which yielded that these levels were higher among
the obese patients with a statistically signiﬁcant difference
(Table 1). HDL level was found lower in obesity group than
control group ( p = 0.0001). The mean plasma insulin level of all
cases was 9.7  7.15 mU/mL, and was 12.95  8.05 mU/mL and
5.82  2.75 mU/mL for the obesity and control groups, respec-
tively. The difference between the insulin levels of the obese
and the control groups was statistically signiﬁcant ( p = 0.0001).
The mean HOMA-IR level of all cases was 37.32  28.89, which
was found to be 50.75  32.13 in the obesity group and 21.26
 11.55 in the control group. The difference between the two
groups was statistically signiﬁcant ( p = 0.0001) (Table 1).
3.3. Echocardiographic ﬁndings
The obesity group's interventricular septal and left ventricular
posterior wall thicknesses (IVST and LVPWT), and left
ventricular internal diameter at diastole (LVID) were compared
to the control group, and all values were found to be
signiﬁcantly higher (Table 2). The mean LVM of all cases
was 160.85  50.73 g, 191.82  44.15 g in the obesity group and123.84  28.42 g in the control group. The obesity and control
groups differed signiﬁcantly in terms of mean LVM ( p = 0.0001)
(Table 2). LVMI of all cases was 85.88  19.22 g/m2, while it was
95.31  17.83 g/m2 and 74.6  14.19 g/m2 in the obesity and the
control groups, respectively. The difference between the two
groups was statistically signiﬁcant ( p = 0.0001) (Table 2).
3.4. Correlation of BMI with glycemic parameters
A positive signiﬁcant correlation of BMI with insulin (r = 0.386,
p = 0.013 and r = 0.317, p = 0.027; respectively) and HOMA IR
(r = 0.324, p = 0.023 and 0.346, p = 0.027, respectively) was noted
in control and obesity groups.
3.5. Correlation of LVMI with laboratory and
anthropometric parameters
No signiﬁcant association of LVMI values was noted with
glycemic and lipid parameters as well as with waist circumfer-
ence in control and obese groups, while in the overall
population, LVMI was positively correlated with waist circum-
ference (r = 0.527, p < 0.001), BMI (r = 0.513, p < 0.001), triglycer-
ide (r = 0.311, p = 0.003), insulin (r = 0.340, p = 0.001), and HOMA-
IR (r = 0.314, p = 0.003) levels (Table 3).
Table 4 – Left ventricular mass with respect to HOMA-IR
categories in the overall study population (below vs.
above median value).
HOMA-IR Left ventricular mass p value
Mean  SD Median
(min–max)
≤27.74 (n = 45) 134.7  39.8 119.7 (75.2–250.1) <0.001
>27.74 (n = 45) 187.0  47.1 185.8 (119.6–344.4)
HOMA-IR: homeostasis model of assessment-estimated insulin
resistance.
Mann–Whitney U test.
Table 3 – The correlation of LVMI with laboratory and anthropometric parameters.
LVMI
Control group Obese group All patients
r p value r p value r p value
Fasting glucose 0.083 0.607 0.065 0.658 0.119 0.265
Waist circumference 0.164 0.185 0.065 0.657 0.527 <0.001
BMI 0.013 0.935 0.061 0.675 0.513 <0.001
LDL 0.12 0.457 0.173 0.235 0.140 0.189
Triglyceridea 0.002 0.988 0.009 0.95 0.311 0.003
Insulina 0.058 0.717 0.069 0.635 0.340 0.001
HOMA-IRa 0.149 0.340 0.155 0.298 0.314 0.003
LVMI: left ventricular mass index; BMI: body mass index; LDL: low-density lipoprotein; HOMA-IR: homeostasis model of assessment-estimated
insulin resistance.
a Spearman's rho correlation analysis was used.
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below and above median value
HOMA-IR values of >27.74 than ≤27.74 were associated
with signiﬁcantly higher LVM values (187.0 + 47.1 vs. 134.7 +
39.8, p < 0.001) (Table 4).
4. Discussion
Our ﬁndings revealed increased levels for plasma glucose,
plasma insulin, and HOMA-IR levels as well as increased levels
for total cholesterol, LDL cholesterol, VLDL cholesterol, and
triglyceride levels in obese than control subjects. Although
obese patients had signiﬁcantly higher values for all echocar-
diographic parameters including IVST, LVPWT, LVID, LVM, and
LVMI, no signiﬁcant correlation of LVMI was noted with
glycemic parameters, lipid parameters, and anthropometrics
in the obese group.
Numerous studies have been conducted investigating the
relationship between LVM increase and obesity, and majority
of them reported to have identiﬁed a correlation in-be-
tween.13,14 In a past study on the relationship of BMI with
changes in cardiac geometry and function, as evaluated by
transthoracic echocardiography in 5898 patients, a signiﬁcant
direct association between BMI and LVM was reported.12
Evaluation of the relationship between obesity and LVH
among 2072 obese adolescents revealed a direct negative
effect of obesity on cardiovascular function staging early inteenage years.27 In a meta-analysis of 22 studies of 5486
patients on the relationship between obesity and LVH, direct
correlation between BMI and LVM was concluded.28
Cuspidi et al. reported higher rate of eccentric than
concentric hypertrophy in obese individuals,28,29 whereas
alike to our ﬁndings in obese patients, data from a study by
Messerli et al. revealed higher rate of concentric hypertro-
phy in obese individuals.30 Prevalence rates of eccentric
and concentric LVH showed a great variability across the
studies, probably due to differences in demographic/clinical
characteristics of obese individuals as well as echocardio-
graphic criteria used to deﬁne left ventricular geometric
patterns.28
There have been studies investigating a suspected causal
relationship between IR and LVH as well.16,18,31 In vitro studies
have shown that with the IR-associated hyperinsulinemia
impact, an increase is observed in the sympathetic stimula-
tion, peripheral vascular resistance, renal sodium retention,
cardiac workload, and the anabolic effect on cardiac proteins.
However, none of the studies have demonstrated a signiﬁcant
relationship between LVM and IR or hyperinsulinemia.20
On the other hand, in the MESA study, insulin resistance
and waist-to-hip ratio were reported to be associated with
concentric left ventricular (LV) remodeling independent of
BMI. The results of MESA supported the emerging hypothesis
that the cardiometabolic phenotype, deﬁned by insulin
resistance and central obesity, may play a critical role in LV
remodeling independently of BMI.32 Nonetheless, it should be
noted that a growing literature support inﬂammation and IR as
a potential etiology for cardiovascular damage in both ‘‘obese’’
and ‘‘nonobese’’ individuals.32 Identiﬁcation of cardiovascular
damage also in nonobese individuals seems to emphasize the
role of visceral fat distribution and adipositopathy.
Insulin level and HOMA-IR values, indicative of IR, were
high in the obesity group patients in this study, and increased
waist circumference was observed to have a signiﬁcant
relationship with insulin level and HOMA-IR. Additionally,
observation of higher levels of total cholesterol and triglyc-
erides and low HDL-cholesterol in the obesity group than in
the control group is indicative of obesity impairing glucose and
lipid metabolisms as expected. An Iranian study, conducted
with 2309 participants, has also determined that central
obesity has a signiﬁcant relationship with lipid parameters
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levels of the obesity group participants were signiﬁcantly
higher than those of the control group participants in this
study. LVH incidence in the obesity group was higher
compared to the control group. LVH, LVM, and LVMI were
not correlated to glucose, lipid parameters, insulin, HOMA-IR,
or waist circumference in this study.
In a past study conducted with 153 healthy individuals
from Turkey, no association of LVH was found with either IR or
fasting insulin level. Obesity is considered an independent risk
factor for LVH.3 Gubbio study, conducted in 2002 in Italy with
91 normotensive patients, failed to determine a signiﬁcant
association of LVM with insulin and IR.31
Another study reported higher levels of LVM increase
among obese than nonobese hypertensive patients (52% vs.
30%). In the same study, the increase in LVM was reported to be
independent of blood pressure values in obese women.34 In
another study conducted with nondiabetic hemodialysis
patients with uremia, insulin resistance and hypertension
were reported to be independent risk factors for LVH.35
Although obese patients in our cohort had increased LVH,
LVM, and LVMI, this increase was not correlated with insulin
level or HOMA-IR.
Correlation of neither anthropometric nor glycemic pa-
rameters with LVMI among obese patients in our cohort seems
contrary to common yet inconclusive literature data on
determinants of LVH. Albeit relatively low sample size and
female gender predominance limit drawing exact conclusions,
this seems a novel ﬁnding indicating the likelihood of
mechanisms other than impaired carbohydrate metabolism
or IR along with the possible role of visceral fat distribution and
adipositopathy to underlie the increase in LVH, LVM, and LVMI
noted among obese patients.
Notably, limited data are available on the relationship of
LVMI with hormones and cytokines, such as adiponectin,
tumor necrosis factor (TNF)-alpha, and interleukin (IL)-6, in the
literature.36 Data from a past study from Turkey revealed the
presence of a signiﬁcant relationship of LVH in nonobese
dialysis patients to the increased levels of adiponectin, TNF-
alpha, and IL-6. On the basis of the association of increased
adiponectin levels with increased proinﬂammatory cytokines
in dialysis patients, adiponectin has been suggested to have a
role in the development of LVH.36
The present study has a number of limitations that should
be taken into account in evaluating the results. First, relatively
low sample size prevented us to perform mutually adjusted
multivariate analysis to evaluate combined effects of glycemic
parameters, lipid parameters, and anthropometrics on LVH
parameters in obese patients. Second, due to inclusion of
comparatively more females, ﬁndings may not prove applica-
ble to general normotensive nondiabetic population. Third,
lack of data on proinﬂammatory status of patients is another
limitation, which otherwise would extend the knowledge
achieved in the current study.
5. Conclusion
In conclusion, our ﬁndings revealed increased IVST, LVPWT,
LVID, LVM, and LVMI and poorer glycemic status and lipidproﬁle among obese patients as compared with control
subjects, whereas no correlation of LVMI with glycemic,
anthropometric, and lipid parameters in obese patients.
Though ﬁndings of the present study suggest increased LVH
in obese subjects compared to controls, it appears that the
increased LVM or LVH is not linked to BMI and insulin
resistance in this study population. Future studies are needed
to explain through which mechanisms obesity causes LVH.
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